$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000142545024000013 Filed on March 08, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$44.69M	$37.61M	$148.7M
YoY Change	41.46%	21.36%	21.62%
Cost Of Revenue	$12.51M	$10.90M	$37.48M
YoY Change	55.86%	11.56%	18.5%
Gross Profit	$32.17M	$26.71M	$111.3M
YoY Change	36.56%	25.87%	22.71%
Gross Profit Margin	72.0%	71.02%	74.8%
Selling, General & Admin	$38.90M	$32.03M	$126.8M
YoY Change	30.18%	16.49%	21.44%
% of Gross Profit	120.9%	119.91%	114.0%
Research & Development	$2.998M	$2.747M	$10.20M
YoY Change	32.07%	35.05%	27.23%
% of Gross Profit	9.32%	10.28%	9.16%
Depreciation & Amortization	$5.028M	$5.187M	$17.39M
YoY Change	30.67%	47.36%	32.72%
% of Gross Profit	15.63%	19.42%	15.63%
Operating Expenses	$41.90M	$34.78M	$138.0M
YoY Change	30.31%	17.77%	18.91%
Operating Profit	-$9.723M	-$8.066M	-$26.75M
YoY Change	13.18%	-2.91%	5.32%
Interest Expense	-$637.0K	$309.0K	$3.178M
YoY Change	-172.39%	-42.88%	-86.48%
% of Operating Profit
Other Income/Expense, Net	-$613.0K	$854.0K	$5.439M
YoY Change	-150.62%	-767.19%	-74.95%
Pretax Income	-$10.34M	-$6.903M	-$21.31M
YoY Change	40.05%	-12.58%	477.72%
Income Tax	-$2.531M	-$212.0K	-$338.0K
% Of Pretax Income
Net Earnings	-$7.805M	-$6.691M	-$20.97M
YoY Change	14.68%	-14.74%	-1767.25%
Net Earnings / Revenue	-17.47%	-17.79%	-14.1%
Basic Earnings Per Share	-$0.34		-$0.92
Diluted Earnings Per Share	-$0.34	-$0.29	-$0.92
COMMON SHARES
Basic Shares Outstanding	23.55M shares	23.35M shares	22.68M shares
Diluted Shares Outstanding	22.82M shares		22.68M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$47.74M	$80.31M	$80.31M
YoY Change	-55.68%	-32.11%	-32.11%
Cash & Equivalents	$21.60M	$31.06M	$49.25M
Short-Term Investments
Other Short-Term Assets	$7.018M	$5.722M	$5.722M
YoY Change	27.93%	5.24%	5.24%
Inventory	$112.7M	$105.9M	$105.9M
Prepaid Expenses
Receivables	$36.28M	$34.62M	$34.62M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$203.7M	$226.5M	$226.5M
YoY Change	-9.45%	-0.1%	-0.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.72M	$41.05M	$41.05M
YoY Change	31.98%	19.72%	19.72%
Goodwill	$91.48M	$83.70M
YoY Change	8.74%	-3.6%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.084M	$2.940M	$2.940M
YoY Change
Total Long-Term Assets	$233.5M	$212.2M	$212.2M
YoY Change	15.97%	5.59%	5.59%
TOTAL ASSETS
Total Short-Term Assets	$203.7M	$226.5M	$226.5M
Total Long-Term Assets	$233.5M	$212.2M	$212.2M
Total Assets	$437.2M	$438.7M	$438.7M
YoY Change	2.56%	2.58%	2.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.74M	$12.65M	$12.65M
YoY Change	18.24%	13.44%	13.44%
Accrued Expenses	$9.772M	$11.33M	$11.33M
YoY Change	56.55%	67.93%	67.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$154.0K	$152.0K	$152.0K
YoY Change	5.48%	5.56%	5.56%
Total Short-Term Liabilities	$45.82M	$41.67M	$41.67M
YoY Change	30.1%	34.97%	34.97%
LONG-TERM LIABILITIES
Long-Term Debt	$10.15M	$9.908M	$9.908M
YoY Change	1300.14%	1198.56%	1198.56%
Other Long-Term Liabilities	$1.815M	$1.112M	$4.663M
YoY Change	181.4%	126.02%	-59.42%
Total Long-Term Liabilities	$20.78M	$20.05M	$14.57M
YoY Change	15.98%	10.14%	18.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.82M	$41.67M	$41.67M
Total Long-Term Liabilities	$20.78M	$20.05M	$14.57M
Total Liabilities	$66.60M	$61.72M	$61.72M
YoY Change	25.34%	25.76%	25.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$205.5M	-$197.7M
YoY Change	11.97%	11.87%
Common Stock	$6.000K	$6.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$370.6M	$377.0M	$377.0M
YoY Change
Total Liabilities & Shareholders Equity	$437.2M	$438.7M	$438.7M
YoY Change	2.56%	2.58%	2.58%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.805M	-$6.691M	-$20.97M
YoY Change	14.68%	-14.74%	-1767.25%
Depreciation, Depletion And Amortization	$5.028M	$5.187M	$17.39M
YoY Change	30.67%	47.36%	32.72%
Cash From Operating Activities	-$6.690M	-$7.543M	-$27.05M
YoY Change	3.54%	125.77%	24.26%
INVESTING ACTIVITIES
Capital Expenditures	$6.460M	$5.942M	$16.88M
YoY Change	30.77%	-1236.14%	68.26%
Acquisitions	$20.69M		$0.00
YoY Change			-100.0%
Other Investing Activities	$2.781M	$23.86M	$60.66M
YoY Change	-92.53%	-200.48%	-158.7%
Cash From Investing Activities	-$3.679M	$17.92M	$41.68M
YoY Change	-111.39%	-177.16%	-136.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$573.0K	9.387M	$7.301M
YoY Change	1491.67%	-26920.0%	-94.63%
NET CHANGE
Cash From Operating Activities	-$6.690M	-7.543M	-$27.05M
Cash From Investing Activities	-$3.679M	17.92M	$41.68M
Cash From Financing Activities	-$573.0K	9.387M	$7.301M
Net Change In Cash	-$9.463M	19.77M	$22.57M
YoY Change	-136.86%	-174.3%	1449.79%
FREE CASH FLOW
Cash From Operating Activities	-$6.690M	-$7.543M	-$27.05M
Capital Expenditures	$6.460M	$5.942M	$16.88M
Free Cash Flow	-$13.15M	-$13.49M	-$43.92M
YoY Change	15.34%	378.53%	38.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	225369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1258000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5050000	usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.orthopediatrics.com/20231231#AssetsNoncurrentExcludingPropertyPlantAndEquipment
CY2023	dei	City Area Code CityAreaCode	574
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.orthopediatrics.com/20231231#AssetsNoncurrentExcludingPropertyPlantAndEquipment
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38242
CY2023	dei	Entity Registrant Name EntityRegistrantName	ORTHOPEDIATRICS CORP
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
CY2023	dei	Local Phone Number LocalPhoneNumber	268-6379
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
CY2023	dei	Trading Symbol TradingSymbol	KIDS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	445100000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23549496	shares
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Indianapolis, Indiana
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31055000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8991000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1972000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1471000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	49251000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	109299000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1373000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1056000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34617000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24800000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	105851000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	78192000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3750000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3966000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	226496000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	226719000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41048000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34286000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	69275000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	64980000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	83699000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	86821000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	15287000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	14921000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2940000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2023Q4	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	171201000	usd
CY2022Q4	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	166722000	usd
CY2023Q4	us-gaap	Assets Assets	438745000	usd
CY2022Q4	us-gaap	Assets Assets	427727000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12649000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11150000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11325000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6744000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	152000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	144000	usd
CY2023Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	10149000	usd
CY2022Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	7815000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7391000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5018000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41666000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30871000	usd
CY2023Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	3551000	usd
CY2022Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	8019000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2980000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5483000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5954000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1112000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	492000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	20054000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18208000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	61720000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	49079000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23378408	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23378408	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22877962	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22877962	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	580287000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	560810000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197742000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176768000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5526000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5400000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	377025000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	378648000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	438745000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	427727000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148732000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122289000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98049000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37479000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31629000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24646000	usd
CY2023	us-gaap	Gross Profit GrossProfit	111253000	usd
CY2022	us-gaap	Gross Profit GrossProfit	90660000	usd
CY2021	us-gaap	Gross Profit GrossProfit	73403000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	51402000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	45053000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	39673000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	75421000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59383000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46061000	usd
CY2023	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	150000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	985000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3609000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10196000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8014000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5543000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	138004000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	116059000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	91427000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-26751000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25399000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-18024000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	198000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2424000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2247000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2261000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5439000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21710000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21312000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3689000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17388000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-338000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4947000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1128000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20974000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1258000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16260000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20704556	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19268255	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22675477	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20947727	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19268255	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16260000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1437000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13891000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21100000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12633000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15676000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	234768000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16260000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	5842000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137000	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	298000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	584000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	6449000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	63000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	139283000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13891000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	378648000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20974000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	10526000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2752000	usd
CY2023	kids	Stock Issued During Period Value Anniversary Installment Payment StockIssuedDuringPeriodValueAnniversaryInstallmentPayment	6178000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20974000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-16260000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	985000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3609000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17385000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13099000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10680000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10526000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6679000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2980000	usd
CY2023	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1372000	usd
CY2022	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	2307000	usd
CY2021	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	2154000	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1163000	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	5032000	usd
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1128000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	9724000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	3983000	usd
CY2021	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	466000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26279000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16938000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-94000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	506000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	637000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1491000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-209000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-567000	usd
CY2023	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	0	usd
CY2022	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	0	usd
CY2021	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	-6342000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6852000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3344000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1095000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	4631000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-536000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	584000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27046000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21766000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13063000	usd
CY2023	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	3097000	usd
CY2022	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
CY2023	us-gaap	Payments To Acquire Business Three Net Of Cash Acquired PaymentsToAcquireBusinessThreeNetOfCashAcquired	546000	usd
CY2022	us-gaap	Payments To Acquire Business Three Net Of Cash Acquired PaymentsToAcquireBusinessThreeNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Business Three Net Of Cash Acquired PaymentsToAcquireBusinessThreeNetOfCashAcquired	0	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	8360000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023	kids	Payments To Acquire Business Four Net Of Cash Acquired PaymentsToAcquireBusinessFourNetOfCashAcquired	0	usd
CY2022	kids	Payments To Acquire Business Four Net Of Cash Acquired PaymentsToAcquireBusinessFourNetOfCashAcquired	31730000	usd
CY2021	kids	Payments To Acquire Business Four Net Of Cash Acquired PaymentsToAcquireBusinessFourNetOfCashAcquired	0	usd
CY2023	kids	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2022	kids	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2021	kids	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	650000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2106000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7908000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	112904000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	46872000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	9250000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48600000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	110122000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16878000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10031000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8103000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	41677000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-113371000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7411000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	31000000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139282000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	63000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	137000	usd
CY2023	kids	Installment Payments InstallmentPayments	2000000	usd
CY2022	kids	Installment Payments InstallmentPayments	3234000	usd
CY2021	kids	Installment Payments InstallmentPayments	0	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	144000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	137000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	131000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7301000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	135974000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	633000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	619000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-658000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22565000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1456000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21126000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10462000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9006000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30132000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33027000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10462000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9006000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	42000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	700000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	56000	usd
CY2023	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	57000	usd
CY2022	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	-234000	usd
CY2021	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	453000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	706000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	213000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	127000	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Spine, BandLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Pediatric Nailing Platform \| Femur, Devise Rail, Orthex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, The Fassier-Duval Telescopic Intramedullary System</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SLIM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nail, The GAP Nail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, The Free Gliding SCFE Screw System</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GIRO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Growth Modulation System, PNP Tibia System, ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mid-C System and Mitchell Ponseti</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation while our clubfoot orthopedic products are manufactured in-house. </span></div>We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants, instruments and braces to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market.
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197742000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>Preparation of our consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-1437000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-1550000	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit	1250000	usd
CY2022Q4	us-gaap	Escrow Deposit EscrowDeposit	1250000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	650000	eur
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1056000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	347000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	433000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	499000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	723000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-5000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	182000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	174000	usd
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	81000	usd
CY2023	kids	Accounts Receivable Acquisition Of Receivables AccountsReceivableAcquisitionOfReceivables	0	usd
CY2022	kids	Accounts Receivable Acquisition Of Receivables AccountsReceivableAcquisitionOfReceivables	160000	usd
CY2021	kids	Accounts Receivable Acquisition Of Receivables AccountsReceivableAcquisitionOfReceivables	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1373000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1056000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	347000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	995000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	1011000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1100000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	reporting_unit
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	985000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3609000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Debt Securities DebtSecurities	1855000	usd
CY2023	kids	Contingent Consideration Accretion Expense ContingentConsiderationAccretionExpense	1372000	usd
CY2021	kids	Contingent Consideration Accretion Expense ContingentConsiderationAccretionExpense	2155000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1800000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	2409000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1906000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	898000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2023	kids	Contributions To Charity Fund ContributionsToCharityFund	286000	usd
CY2022	kids	Contributions To Charity Fund ContributionsToCharityFund	524000	usd
CY2021	kids	Contributions To Charity Fund ContributionsToCharityFund	88000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	128648000	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	113899000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	2110000	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12810000	usd
CY2021Q4	us-gaap	Share Price SharePrice	64.83
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	reporting_unit
CY2021Q4	us-gaap	Goodwill Goodwill	72349000	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	5450000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	16528000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-7506000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	86821000	usd
CY2023	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-1936000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1186000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	83699000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	91267000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21992000	usd
CY2023Q4	kids	Accumulated Impairment Of Intangible Assets Finite Lived AccumulatedImpairmentOfIntangibleAssetsFiniteLived	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	69275000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	79823000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14843000	usd
CY2022Q4	kids	Accumulated Impairment Of Intangible Assets Finite Lived AccumulatedImpairmentOfIntangibleAssetsFiniteLived	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	64980000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7149000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5977000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4531000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7577000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7379000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7339000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	6908000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	6281000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	33791000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	69275000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80636000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	65090000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39588000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30804000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41048000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34286000	usd
CY2023	us-gaap	Depreciation Depreciation	10236000	usd
CY2022	us-gaap	Depreciation Depreciation	7121000	usd
CY2021	us-gaap	Depreciation Depreciation	6148000	usd
CY2023Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	4279000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	3282000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	7046000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	3462000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	11325000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	6744000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	11063000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	907000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1003000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	152000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	144000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9908000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	763000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	152000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	144000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	152000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	160000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	168000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	176000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	10407000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	11063000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	42000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	525000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	56000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-338000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4947000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1128000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12582000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	6451000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9232000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8730000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-10140000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8156000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21312000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3689000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17388000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	85000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	68000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	740000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	17000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	825000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	85000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1163000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2018000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1128000	usd
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-3014000	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-338000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4947000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1128000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.063
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.064
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2023	kids	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent	-0.003
CY2022	kids	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent	0.009
CY2021	kids	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent	-0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.096
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.075
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.033
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.221
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.119
CY2023	kids	Effective Income Tax Rate Reconciliation Unborn Foreign Tax Deduction Percent EffectiveIncomeTaxRateReconciliationUnbornForeignTaxDeductionPercent	-0.005
CY2022	kids	Effective Income Tax Rate Reconciliation Unborn Foreign Tax Deduction Percent EffectiveIncomeTaxRateReconciliationUnbornForeignTaxDeductionPercent	0.068
CY2021	kids	Effective Income Tax Rate Reconciliation Unborn Foreign Tax Deduction Percent EffectiveIncomeTaxRateReconciliationUnbornForeignTaxDeductionPercent	-0.015
CY2023	kids	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential Us Benefit Of Foreign Branches EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferentialUSBenefitOfForeignBranches	0.086
CY2022	kids	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential Us Benefit Of Foreign Branches EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferentialUSBenefitOfForeignBranches	0.644
CY2021	kids	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential Us Benefit Of Foreign Branches EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferentialUSBenefitOfForeignBranches	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.044
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.241
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.578
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.331
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.016
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.341
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.063
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	5979000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	5804000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3158000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2534000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42199000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38443000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	176000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	176000	usd
CY2023Q4	kids	Deferred Tax Assets Tax Interest Carryforwards DeferredTaxAssetsTaxInterestCarryforwards	134000	usd
CY2022Q4	kids	Deferred Tax Assets Tax Interest Carryforwards DeferredTaxAssetsTaxInterestCarryforwards	520000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1122000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	787000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	52768000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	48264000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41927000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36778000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10841000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11486000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	14426000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	15737000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1898000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1703000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16324000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	17440000	usd
CY2023Q4	kids	Deferred Tax Assets Liability Foreign Currency Translation DeferredTaxAssetsLiabilityForeignCurrencyTranslation	0	usd
CY2022Q4	kids	Deferred Tax Assets Liability Foreign Currency Translation DeferredTaxAssetsLiabilityForeignCurrencyTranslation	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5483000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5954000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	118930000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	76944000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	26260000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	176000	usd
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation	23920000	usd
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	1062000	usd
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	9736000	usd
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease	22430000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	3230000	usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4422	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2010	shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	670	shares
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-20974000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1258000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16260000	usd
CY2023	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	0	usd
CY2022	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	23000	usd
CY2022	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	23000	usd
CY2021	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20974000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-20974000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1235000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1235000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16260000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16260000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	900000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22675477	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20704556	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19268255	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22675477	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20947727	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19268255	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	606304	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	416960	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	375084	shares
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148732000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122289000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98049000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148732000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122289000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98049000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	718000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	510000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1084000	usd
CY2021Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1900000	usd
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	1820000	usd
CY2023Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	1456000	usd
CY2023	kids	Research And Development Arrangement Contract To Perform For Others Minimum Annual Royalty Payment ResearchAndDevelopmentArrangementContractToPerformForOthersMinimumAnnualRoyaltyPayment	10000	usd
CY2023	dei	Auditor Firm AuditorFirmId	34

Files In Submission

Name	View Source	Status
0001425450-24-000013-index-headers.html	Edgar Link	pending
0001425450-24-000013-index.html	Edgar Link	pending
0001425450-24-000013.txt	Edgar Link	pending
0001425450-24-000013-xbrl.zip	Edgar Link	pending
deloitteconsent-filing2023.htm	Edgar Link	pending
exhbit322-cfocertification.htm	Edgar Link	pending
exhibit211subsidiariesofor.htm	Edgar Link	pending
exhibit24-poa2023.htm	Edgar Link	pending
exhibit311-ceocertificatio.htm	Edgar Link	pending
exhibit312-cfocertificatio.htm	Edgar Link	pending
exhibit321-ceocertificatio.htm	Edgar Link	pending
exhibit45descriptionofcapi.htm	Edgar Link	pending
exhibit97clawbackpolicy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
kids-20231231.htm	Edgar Link	pending
kids-20231231.xsd	Edgar Link	pending
kids-20231231_def.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
kids-20231231_htm.xml	Edgar Link	completed
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
kids-20231231_lab.xml	Edgar Link	unprocessable
kids-20231231_pre.xml	Edgar Link	unprocessable
kids-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2024 Q1 Form 10-K Financial Statement

#000142545024000013 Filed on March 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2024 Q1 Form 10-K Financial Statement

#000142545024000013 Filed on March 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids